Everest Medicines Past Earnings Performance
Past criteria checks 0/6
Everest Medicines has been growing earnings at an average annual rate of 35.5%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 139.8% per year.
Key information
35.5%
Earnings growth rate
75.5%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 139.8% |
| Return on equity | -21.2% |
| Net Margin | -251.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Everest Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 419 | -1,053 | 537 | 505 |
| 31 Mar 24 | 272 | -949 | 467 | 522 |
| 31 Dec 23 | 126 | -844 | 397 | 540 |
| 30 Sep 23 | 73 | -424 | 440 | 646 |
| 30 Jun 23 | 21 | -3 | 483 | 753 |
| 31 Mar 23 | 17 | -125 | 543 | 781 |
| 31 Dec 22 | 13 | -247 | 603 | 810 |
| 30 Sep 22 | 7 | -770 | 581 | 759 |
| 30 Jun 22 | 1 | -1,294 | 558 | 708 |
| 31 Mar 22 | 1 | -1,151 | 500 | 661 |
| 31 Dec 21 | 0 | -1,009 | 441 | 613 |
| 30 Sep 21 | 0 | -3,213 | 395 | 540 |
| 30 Jun 21 | 0 | -5,418 | 350 | 467 |
| 31 Mar 21 | 0 | -6,154 | 315 | 423 |
| 31 Dec 20 | 0 | -5,658 | 311 | 377 |
| 31 Mar 20 | 0 | -10 | 118 | 208 |
| 31 Dec 19 | 0 | -215 | 55 | 151 |
Quality Earnings: 1952 is currently unprofitable.
Growing Profit Margin: 1952 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1952 is unprofitable, but has reduced losses over the past 5 years at a rate of 35.5% per year.
Accelerating Growth: Unable to compare 1952's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1952 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.8%).
Return on Equity
High ROE: 1952 has a negative Return on Equity (-21.2%), as it is currently unprofitable.